Vertex Pharma (VRTX) free cash flow was $3.2B in FY2025 (+504% YoY). The tables below show the complete quarterly and annual free cash flow history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Free Cash Flow
Fiscal Year
Free Cash Flow
YoY
2025
$3.2B
+504%
2024
-$790M
-124%
2023
$3.3B
-16%
2022
$3.9B
+63%
2021
$2.4B
-20%
2020
$3.0B
+100%
2019
$1.5B
+27%
2018
$1.2B
+58%
2017
$746M
+315%
2016
$180M
+137%
2015
-$491M
+23%
2014
-$634M
-466%
2013
-$112M
-157%
2012
$197M
+300%
2011
$49M
+107%
2010
-$673M
-49%
2009
-$451M
-74%
2008
-$259M
Recent Quarterly Free Cash Flow
Quarter
Free Cash Flow
Q1 2026
$1.3B
Q4 2025
$349M
Q3 2025
$1.1B
Q2 2025
$927M
Q1 2025
$778M
Q4 2024
$492M
Q3 2024
$1.3B
Q2 2024
-$3.8B
Q1 2024
$1.2B
Q4 2023
$118M
Q3 2023
$1.2B
Q2 2023
$1.1B
Source: VRTX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.